Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00578461 | T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE(REGKINE) | terminated | N/A | 26 | Baylor College of MedicineOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00578539 | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE(REGALE) | terminated | N/A | 24 | Baylor College of MedicineOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | terminated | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | terminated | Phase 1 / Phase 2 | 62 | CephalonINDUSTRY | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00664586 | A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors | terminated | Phase 1 | 21 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | terminated | Phase 2 | 43 | Asan Medical CenterOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)(VEIL) | terminated | Phase 2 | 1 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT02096341 | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | terminated | Phase 2 | 6 | Januario Castro, M.D.OTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | terminated | Phase 2 | 5 | Januario Castro, M.D.OTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 16, 2015 | clinicaltrials |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 10 | Georgetown UniversityOTHER | 1 | Dec 15, 2015 | clinicaltrials |
| NCT01049113 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | terminated | Phase 1 | 7 | Traws Pharma, Inc.INDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00512980 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | terminated | Phase 2 | — | University of CologneOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT00384150 | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 16 | BiogenINDUSTRY | 0 | Nov 26, 2015 | clinicaltrials |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01050946 | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit(Haplo/Cord) | terminated | Phase 2 | 1 | Medical College of WisconsinOTHER | 0 | Nov 20, 2015 | clinicaltrials |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2015 | clinicaltrials |
| NCT00671112 | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | terminated | Phase 1 | 30 | Brian Hill, MD, PhDOTHER | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00363636 | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 340 | BiogenINDUSTRY | 0 | Oct 2, 2015 | clinicaltrials |
| NCT00498914 | Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects | terminated | Phase 2 | 41 | Astellas Pharma IncINDUSTRY | 4 | Sep 4, 2015 | clinicaltrials |
| NCT01119794 | Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab | terminated | Phase 2 | 10 | Brown UniversityOTHER | 1 | Aug 26, 2015 | clinicaltrials |
| NCT00475917 | A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies | terminated | Phase 1 | 28 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00526838 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | terminated | Phase 1 | 84 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00954005 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma(R-GO) | terminated | Phase 1 / Phase 2 | 56 | German Low Grade Lymphoma Study GroupOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | terminated | Phase 2 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2015 | clinicaltrials |
| NCT00250718 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 3, 2015 | clinicaltrials |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT01642563 | Italian Platelet Technology Assessment Study(IPTAS) | terminated | Phase 3 | 456 | Centro Nazionale SangueOTHER_GOV | 1 | Jul 28, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 5 | Duke UniversityOTHER | 1 | Jul 15, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 51 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 3, 2015 | clinicaltrials |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma | terminated | Phase 2 | 23 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | terminated | Phase 3 | 48 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2015 | clinicaltrials |
| NCT01016795 | Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma(SCF980266) | terminated | Phase 2 | 32 | Aalborg University HospitalOTHER | 4 | Jun 25, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
Data updated 23 days agoSource updated May 4, 2016source: clinicaltrials